Effect of latanoprost on central corneal thickness in unilateral normal-tension glaucoma.
OBJECTIVE
To evaluate the effect of latanoprost on central corneal thickness (CCT) in patients with unilateral normal-tension glaucoma (NTG).


METHODS
A total of 38 patients, with unilateral NTG, who were being treated in our glaucoma clinic and were receiving 0.005% latanoprost monotherapy over 24 months, were included in this study. The data were collected, retrospectively, with reviewing of the charts. The mean CCT and the CCT reduction from the baseline were assessed before the treatment, and at 3, 6, 9, 12, and 24 months after the initiation of the treatment. An unaffected eye was also evaluated for the control group. All the measurements were performed with a commercially available ultrasound pachymeter.


RESULTS
There were no significant differences between the eyes for the baseline intraocular pressure and CCT. The mean CCT trend decreased, except at 9 months after the treatment in the latanoprost group (affected eye), but only statistically significant after 24 months of treatment by using paired-sample t-test [544.6±38.4 vs. 540.3±37.8 μm (P=0.013)]. There was no statistically significant changes of CCT between the groups with repeated measures analysis of variance (P=0.635).


CONCLUSIONS
Topical therapy with latanoprost may decrease the CCT, over a period of 24 months, in patients with NTG. These data should be taken into consideration in a long-standing latanoprost treatment of NTG.
Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.
Ja Young
JY
You
Byung Joo
BJ
Cho
D060433:Administration, Ophthalmic; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003315:Cornea / Q000187:drug effects* / Q000378:metabolism; D063171:Corneal Pachymetry; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure; D000077338:Latanoprost; D057066:Low Tension Glaucoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D013997:Time Factors
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost